The Harvey Family Foundation

What The Harvey Family Foundation does

The Harvey Family Foundation is a privately-held family foundation headquartered in Edmond, Oklahoma, founded by Dr. Mark Harvey, a Cardiac Electrophysiology specialist who practices at Oklahoma Heart Hospital and completed training at the University of Michigan Hospitals. The foundation exists to catalyze scientific discoveries that benefit people worldwide, with a mission driven by a deeply personal motivation: two of Dr. Harvey's adult children live with cystic fibrosis. Its primary operating activity is making targeted, strategic grants to the scientific community rather than selling products or services, and it explicitly avoids commercial revenue mechanics such as pricing models or sales motions.

The foundation's flagship technical commitment is its co-funding, with the Cystic Fibrosis Foundation, of a three-year gene therapy program platform at the Massachusetts Institute of Technology. The MIT program centers on PASTE, a CRISPR-based architecture designed to insert large pieces of DNA into the genome, a differentiating methodological approach versus standard CRISPR-Cas9 cuts. The technology is being applied toward cystic fibrosis treatments, but the platform architecture is positioned by the foundation as capable of broader gene-therapy impact over time. The foundation describes its role as catalytic: providing financial resources, brokering connections between scientists, venture capitalists, and biotech investors, and creating dynamic research opportunities.

Commercially, the Harvey Family Foundation operates as a philanthropic grant-maker rather than a revenue-generating business. Its "go-to-market" consists of direct relationship building with research scientists, biotech investors, and aligned disease foundations, with no disclosed marketing or sales channels. It also runs a legacy-gift facilitation initiative intended to help smaller donors contribute through their estates to organizations assisting the cystic fibrosis community, expanding the foundation's role from direct grantmaker to donor-ecosystem convener. The entity is privately controlled by the Harvey family, has no parent company, no subsidiaries, and no public listing.

Name

The Harvey Family Foundation

Legal name

Harvey Family Foundation

Website

https://harveyff.org

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

The Harvey Family Foundation is an Oklahoma-based private family foundation founded by Dr. Mark Harvey that catalyzes scientific discoveries in cystic fibrosis through strategic grant-making, including co-funding a PASTE CRISPR gene therapy program at MIT alongside the Cystic Fibrosis Foundation.

Ownership category

akta.pro rank

Product category

Family Foundation / Scientific Philanthropy

NAICS

Grantmaking Foundations (813211)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industry

Community Foundations (BPAGAKAB)

Keywords

• Scientific philanthropy grants
• Family foundation giving
• Cystic fibrosis research
• Gene therapy funding
• CRISPR research grants

Headquarters

HQ city

Edmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others, Operations, Personnel

Core offering

The Harvey Family Foundation is a grant-making family foundation that catalyzes scientific discoveries by providing targeted, strategic gifts to the scientific community, with a focus on cystic fibrosis gene therapy research. Its principal funded initiative is a co-funded three-year gene therapy program at MIT centered on PASTE, a CRISPR platform for inserting large DNA sequences into the genome. The foundation also facilitates legacy gift discussions so that smaller donors can collectively support organizations serving the cystic fibrosis community.

Product overview

The Harvey Family Foundation is a grant-making family foundation focused on catalyzing scientific discoveries in cystic fibrosis research. The foundation does not offer a product or service in the traditional sense; rather, it operates as a philanthropic organization that makes strategic gifts and grants to the scientific community. The foundation's primary activity is facilitating connections and funding research programs, including a three-year gene therapy program platform at MIT focused on PASTE, a CRISPR-based gene therapy platform. The foundation also works to help smaller donors engage in collective giving through legacy gift facilitation.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Scientific Research Grants

Quantifiable outcome

• Three-year gene therapy program platform at MIT focused on PASTE CRISPR technology

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• MIT (Massachusetts Institute of Technology)coreStrategic or Co-development PartnerCo-funding a three-year gene therapy program platform at MIT. The grant focuses on PASTE, a new CRISPR platform designed to insert large pieces of DNA into the genome, with the goal of developing treatments for cystic fibrosis.
• Cystic Fibrosis FoundationcoreStrategic or Co-development PartnerStrategic collaboration through grant giving, co-funding a three-year gene therapy program at MIT. Also working together to help smaller donors find ways to engage in collective giving by facilitating discussions about leaving legacy gifts to organizations that assist and advocate for people with cystic fibrosis.

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Howard Hughes Medical Institute: Major biomedical research organization funding investigator-initiated science and gene-editing research at scale. Comparable as a high-impact funder of frontier biomedical research including CRISPR-related work, though operating as a research institute rather than a grantmaking foundation.
• Doris Duke Charitable Foundation: Established family-sourced foundation with a major Medical Research Program that funds clinical research and physician-scientists. Highly comparable as a family-originated, mission-driven grantmaker in biomedical research, though at much larger scale and broader disease focus than Harvey.
• The Leona M. and Harry B. Helmsley Charitable Trust: Large private foundation with significant Health and Medical Research grant portfolios. Comparable as a private, family-originated foundation directing strategic grant capital into disease-focused research, but with substantially larger endowment and broader program areas.
• Pew Charitable Trusts: Large public charity funding biomedical research programs including the Pew Scholars program in biomedical sciences. Comparable as an established philanthropic grantmaker directing strategic capital into biomedical research, though with broader programmatic scope than Harvey.
• Wellcome Trust: Global charitable foundation funding biomedical research and innovation, including significant support for CRISPR and gene therapy platforms. Comparable as a strategic philanthropic funder of cutting-edge genetic medicine, though at multibillion-dollar scale with global mandate.
• Bill & Melinda Gates Foundation: The world's largest private foundation, with major Global Health and Life Sciences programs that fund gene therapy and CRISPR-adjacent research. Comparable as a catalytic, mission-driven grantmaker in health research, though with vastly broader scope and resources.

Direct peers

• Klarman Family Foundation: Family foundation supporting scientific research, medical innovation, and targeted philanthropic initiatives. Comparable as a private family foundation deploying strategic grants in biomedical science at a scale likely similar to Harvey.
• Cystic Fibrosis Foundation: The leading U.S. nonprofit focused on cystic fibrosis research and care, and Harvey Family Foundation's explicit co-funding partner on the MIT PASTE CRISPR program. Directly comparable as a disease-focused grantmaker in CF, but operating at vastly greater scale.
• Pershing Square Foundation: Family foundation funding health and medical research, including gene therapy and translational science. Comparable as a family-controlled, mission-aligned grantmaker backing frontier biomedical research.

Emerging players

• Chan Zuckerberg Initiative: Philanthropic vehicle with a science program supporting biomedical research and rare disease initiatives through the Chan Zuckerberg Rare As One Network. Comparable as a private philanthropic funder actively engaged in disease-specific research and researcher networks, including in CF-adjacent areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/the-harvey-family-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Harvey Family Foundation